SCHEMBL23554273

SCHEMBL23554273

COC(=O)c1ccc2c(n1)C(=O)N(C(=O)OC(C)(C)C)C2

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.41
PIK3CA P42336 2/20 0.40
MTOR P42345 2/20 0.40
HDAC1 Q13547 3/20 0.36
HDAC6 Q9UBN7 2/20 0.36
GPR119 Q8TDV5 1/20 0.36
SLC6A15 Q9H2J7 1/20 0.35
ESR2 Q92731 1/20 0.35
MAPT P10636 1/20 0.33
PTPN1 P18031 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CHRM4 P08173 1/20 0.32
DRD2 P14416 1/20 0.32
HTR7 P34969 1/20 0.32
KDM1A O60341 1/20 0.32
NAMPT P43490 1/20 0.32
PTGER4 P35408 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21847688 0.82 PIK3CA (0.40) NR1H2PIK3CAMTORHDAC1GPR119
SCHEMBL29226277 0.81 PIK3CA (0.39) NR1H2PIK3CAMTORHDAC1HDAC6
SCHEMBL21847679 0.81 ESR2 (0.40) NR1H2PIK3CAMTORHDAC1HDAC6
SCHEMBL29226367 0.79 PIK3CA (0.38) NR1H2PIK3CAMTORHDAC1HDAC6
SCHEMBL21847682 0.79 PIK3CA (0.38) NR1H2PIK3CAMTORHDAC1HDAC6
SCHEMBL21847886 0.79 NR1H2 (0.35) NR1H2PIK3CAMTORHDAC1HDAC6
SCHEMBL21847689 0.75 PIK3CA (0.36) NR1H2PIK3CAMTORHDAC1HDAC6
SCHEMBL26091660 0.75 NR1H2 (0.48) NR1H2PIK3CAMTORHDAC1GPR119
SCHEMBL23554856 0.74 PTGER4 (0.42) SLC6A15MAPTMEN1KMT2ACHRM4
SCHEMBL21847643 0.74 MAPK1 (0.45) PIK3CAMTORGPR119MAPTNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230136194-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2023-05-04 US disclosed
US-20230136194-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2023-05-04 US disclosed
WO-2021121294-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 上海赛默罗生物科技有限公司 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230136194-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF ABCG2, CYP4F8, CYP3A5 NR1H2 682/4885PIK3CA 780/4885MTOR 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.